Ikena Oncology   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2016)

Organization Overview

First Clinical Trial
2019
NCT04200963
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ikena Oncology

Active Ingredients

Drugs in Phase 2 Trials (2)

Key: Ikena Oncology (0) Acquired (2)

grapiprant (2 trials)

pembrolizumab (keytruda) (3 trials)

Drugs in Phase 1 Trials (6)

Key: Ikena Oncology (4) Acquired (2)

ik-175 (1 trial)

ik-930 (1 trial)

kyn-175 (1 trial)

nivolumab (opdivo) (1 trial)

py159 (1 trial)

py314 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Urinary Bladder Diseases (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 7
  • # of Trial APIs: 8